CompletedPhase 4ACTRN12605000596606
SAFETY AND EFFICACY OF AMBISOME VS CONVENTIONAL AMPHOTERICIN B IN THE TREATMENT OF PATIENTS WITH SUSPECTED OR CONFIRMED MYCOSIS
Sponsor
Dr. Michael Whitby (Princess Alexandra Hsp, QLD)
Enrollment
104 participants
Start Date
Apr 1, 2007
Study Type
Interventional
Conditions
Eligibility
Sex: Both males and females
Inclusion Criteria1
- Highly suspected or confirmed invasive fungal infection.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Systemic treatment of mycosis with either liposomal amphotericin B (AmBisome by Gilead Sciences) or conventional amphotericin B (Fungizone by Bristol-Myers Squibb). Treatment will be given for a minim
Systemic treatment of mycosis with either liposomal amphotericin B (AmBisome by Gilead Sciences) or conventional amphotericin B (Fungizone by Bristol-Myers Squibb). Treatment will be given for a minimum of 14 days. However, if the patient's condition deteriorates after 10 days of therapy, the patient will be switched to salvage therapy (AmBisome 5mg/kg/day). TOtal duration of therapy depends on the infection and the patient's condition.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000596606